Maxigesic IV Licensed for Japan

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that they have entered into an exclusive development, license and supply agreement with MIKASASEIYAKU CO., LTD. ("Mikasa") for the development and commercialization of AFT's intravenous fixed-dose combination analgesic, Maxigesic IV (also known as Combogesic IV) in Japan, the third largest pharma market in the world. Under the agreement, AFT grants Mikasa an exclusive license to seek marketing authorization for and commercialize the product throughout Japan. AFT will be responsible for developing and supplying the product, while Mikasa will lead regulatory submissions to Japan's Pharmaceuticals and Medical Devices Agency (PMDA), pursue marketing authorization, and development and commercialization of the product in the Japanese market. Maxigesic IV is a proprietary, non-opioid injectable combination of paracetamol (1000 mg) and ibuprofen (300 mg) developed by AFT for the management of pain. The collaboration is intended to make this treatment option available to patients and healthcare providers in Japan. Under the agreement, AFT will receive an upfront license fee, development milestones linked to regulatory submission progress and reimbursement pricing in Japan, with Royalties earned on commercial sales following launch. AFT will also be supplying the finished product to Mikasa. AFT was assisted with this licensing agreement in Japan by Shin Nippon Biomedical Laboratories Ltd (TSE: 2395). Released for, and on behalf of, AFT Pharmaceuticals Limited by Stuart Houliston, Chief Financial Officer. For more information: Investors Dr Hartley Atkinson Managing Director AFT Pharmaceuticals Tel: +64 9488 0232 Media Richard Inder The Project Tel: +64 21 645 643